Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)

被引：0
|
作者：
Cohen, Stanley [1 ]
Czeloth, Niklas [2 ]
Lees, Eric [3 ]
Klimiuk, Piotr A. [4 ,5 ]
Peter, Nuala [6 ]
Jayadeva, Girish [2 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Inland Rheumatol, Upland, CA USA
[4] Med Univ Bialystok, Bialystok, Poland
[5] Gabinet Internistyczno Reumatol, Bialystok, Poland
[6] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2522
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)
    Cohen, Stanley B.
    Czeloth, Niklas
    Lee, Eric
    Klimiuk, Piotr A.
    Peter, Nuala
    Jayadeva, Girish
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 1097 - 1105
  • [2] Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study
    Cohen, Stanley B.
    Alonso-Ruiz, Alberto
    Klimiuk, Piotr A.
    Lee, Eric
    Peter, Nuala
    Czeloth, Niklas
    Jayadeva, Girish
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [3] Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
    Cohen, Stanley B.
    Alonso-Ruiz, Alberto
    Klimiuk, Piotr A.
    Lee, Eric C.
    Peter, Nuala
    Sonderegger, Ivo
    Assudani, Deepak
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (06) : 914 - 921
  • [4] SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND ADALIMUMAB ORIGINATOR REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)
    Cohen, S.
    Alonso-Ruiz, A.
    Klimiuk, P. A.
    Lee, E.
    Peter, N.
    Sonderegger, I.
    Assudani, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 553 - 553
  • [5] Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study
    Menter, Alan
    Arenberger, Petr
    Balser, Sigrid
    Beissert, Stefan
    Cauthen, Ashley
    Czeloth, Niklas
    Soung, Jennifer
    Jazayeri, Sasha
    Weisenseel, Peter
    Jayadeva, Girish
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 87 - 96
  • [6] EFFICACY AND SAFETY RESULTS OF A PHASE III STUDY COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
    Alten, R.
    Glover, J.
    Matsunaga, N.
    Chisholm, D.
    Genovese, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 59 - 59
  • [7] BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY
    Hanauer, Stephen B.
    Schreiber, Stefan
    Balser, Sigrid E.
    Brockstedt, Ekkehard
    Moschetti, Viktoria
    Liedert, Bernd J.
    GASTROENTEROLOGY, 2020, 158 (06) : S1192 - S1193
  • [8] Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and OpenLabel Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)
    Genovese, Mark C.
    Glover, Josephine
    Matsunaga, Nobuhito
    Chisholm, Diane
    Alten, Rieke
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [9] SAFETY, IMMUNOGENICITY AND EFFICACY OF THE PROPOSED BIOSIMILAR MSB11022 (MODIFIED FORMULATION) COMPARED WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: AURIEL-RA, A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY
    Edwards, Christopher
    Chyrok, Veronica
    Monnet, Joelle
    Ullmann, Martin
    Vlachos, Pantelis
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 707 - 707
  • [10] Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis
    Weinblatt, Michael E.
    Taylor, Peter C.
    Keystone, Edward C.
    Ortmann, Robert A.
    Issa, Maher
    Xie, Li
    de Bono, Stephanie
    Tanaka, Yoshiya
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345